TARO manufactures, markets and distributes OTC and prescription pharmaceuticals primarily in the Unites States,Canada and Israel, offering topical corticosteroids and antifungal cream products. For the FY ended 12/31/00, net sales rose 24% to $103.8M. Net income increased 81% to $10M. Revenues reflect the introduction of new products. Earnings also benefitted from increases in gross margins due to improved manufacturing efficiencies.

April 10, 2001

Taro Pharmaceutical markets and distributes prescription and OTC pharmaceutical products. The company’s main focus has been the off-patent dermatological market, but recent FDA approval on its generic drug for cardiac arrhythmias has got investors on a buying spree. Also adding interest to the rally has been the potential for the company to split its stock. Currently, TARO has 10.71 million shares outstanding and 50 million authorized, well enough for a 2:1 stock split. Although the company has never split its stock before, the recent run to all time highs looks promising. Moving to the chart, the stock is clearly on a breakout now that higher levels are being confirmed by an expansion in volume. On Tuesday, TARO soared to a new 52-week high of $50.50 on good volume of 203,400 shares traded. A move above this level in the upcoming week could be a good signal for traders to place their orders. Support will likely reside at the 5-dma of 47.64. TARO’s strong uptrend is bolstered by good technical readings in the MACD and OBV indicators, which suggests that a sustainable move is possible. We’ll look for potential entry points to arise when TARO pushes though $50.50 on daily volume above the three-month average of 144,400 shares. We’ll set our stops at $44 for downside protection.

Picked on April 10th@ $49.45
Change since picked 0.00
Stop Loss @ $44.00